Drug Type Small molecule drug |
Synonyms 4-((6-chloro-2-methoxyacridin-9-yl)amino)-2-((4-(2-(dimethylamino)ethyl) piperazin-1-yl) methyl) phenol |
Target |
Mechanism ERCC1 inhibitors(ERCC excision repair 1, endonuclease non-catalytic subunit inhibitors), ERCC4 inhibitors(ERCC excision repair 4, endonuclease catalytic subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CA | 22 Aug 2019 |